Ginkgo biloba for cognitive impairment and dementia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Birks, Jacqueline ^a   Evans, John Grimley ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

*Ginkgo biloba; *Phytotherapy; Cognition disorders *drug therapy ; Dementia *drug therapy ; Humans; Plant extracts *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

DIHYDROERGOTOXINE; GINKGO BILOBA EXTRACT; GINKGOLIDE DERIVATIVE; GLYCOSIDE; NICERGOLINE; TACRINE; VINCAMINE;

AGITATION; BACKACHE; BEHAVIOR DISORDER; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DATA BASE; DEMENTIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMOTION; GINKGO BILOBA; HUMAN; INSTRUMENTATION; LOW DRUG DOSE; NAUSEA AND VOMITING; NEUROLOGIC EXAMINATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SAFETY; SIDE EFFECT; TINNITUS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 69549105254     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003120.pub3     Document Type: Review

References (122)

1. Arrigo A, Cattaneo S. Clinical and psychometric evaluation of Ginkgo biloba extract in chronic cerebro-vascular diseases. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV editor(s). Effects of Ginkgo biloba extract on organic cerebral impairment. John Libbey Eurotext Ltd, 1985:85-89
2. Arrigo A. Behandlung der chronischen zerebrovaskulaeren Insuffizienz mit Ginkgo-biloba-Extrakt. Therapiewoche 1986;36:5208-5218 (Pubitemid 17213545)
3. Augustin P. Le Tanakan en geriatrie. Etude clinique et psychometrique chez 189malades d'hospice. Psychologie Medicale 1976;8:123-130
4. * Brautigam MRH, Blommaert FA, Verleye G, Castermans J, Jansen Steur ENH, Kleijnen J. Treatment of age-related memory complaints with Ginkgo biloba extract: a randomized placebo-controlled study. Phytomedicine 1998;5(6):425-434
5. Brüchert E, Heinrich SE, Ruf-Kohler P.Wirksamkeit von LI 1370 bei älteren Patienten mit Hirnleistungsschwäche. Multizentrische Doppelblindstudie des Fachverbandes Deutsche Allgemeinärtze. Münch Med Wochenschr 1991;133:S9-S14.
6. * Chartres JP, Bonnan P, Martin G.Dosage reduction in psychotropic medications administered to aged institutionalized patients: A double-blind study with Gingko Biloba extract 761 and placebo [Reduction de posologie de medicaments psychotropes chez des personnes agees vivant en institution. Etude a double-insu chez des patients prenant soit de l'extrait de Ginkgo biloba 761 soit du placebo]. Psychologie-Medicale 1987;19(8):1365-1375
7. McCarney R, Fisher P, Iliffe S, van Haselen R, Griffin M, van der Meulen J, Warner J.Ginkgo biloba for mild tomoderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry 2008. [DOI: 10.1002/gps.2005]
8. Von Eckmann F, Schlag H. Kontrollierte Doppelblind-Studie zum Wirksamkeitnachweis von Tebonin forte bei patienten mit zerebrovaskulaerer Insuffizienz. Fortschr. Med. 1982;100:1474-1478 (Pubitemid 13231596)
9. * Von Eckmann F. Cerebral insufficiency - treatment with Ginkgo-biloba extract. Time of onset of effect in a double-blind study with 60 inpatients. [Hirnleistungsstorungen - Behandlung mit Ginkgo-biloba-Extrakt. Zeitpunkt des Wirkungseintritts in einer Doppelblindstudie mit 60 stationaren Patienten.]. Fortschr Med 1990;108(29):557-560
10. * Graessel E. Effect of Ginkgo-biloba extract onmental performance. Double-blind study using computerized measurement conditions in patients with cerebral insufficiency [Einfluss von Ginkgo-biloba-Extrakt auf die geistige Leistungsfahigkeit. Doppelblindstudie unter computerisierten Messbedingungen bei Patienten mit Zerebralinsuffizienz.]. Fortschr Med 1992;110(5):73-76
11. * Haase J, Halama P, Horr R. Effectiveness of brief infusions with Ginkgo biloba Special Extract EGb 761 in dementia of the vascular and Alzheimer type [Wirksamkeit kurzdauernder Infusionsbehandlungen mit Ginkgo-biloba- Spezialextrakt EGb 761 beiDemenz vom vaskularen und Alzheimer-Typ]. Z Gerontol Geriatr 1996;29(4):302-309
12. Horr R, Kieser M. Ginkgo biloba special extract EGb 761 - an antidementia drug [Ginkgo-biloba-Spezialextrakt EGb 761 - ein Antidementivum]. Fortschr Med 1998;116(3):39-40. (Pubitemid 28064603)
13. Halama P, Bartsch G, Meng G. Cerebrovascular insufficiency - placebo-controlled, randomized, double blind-trial on the effect of Gingko biloba-extract. Fortschritte der Medizin 1988b; Vol.106, issue 19:54-60. (Pubitemid 18189565)
14. * Halama von P, Bartsch G, Meng G. Disorders of brain performance of vascular origin. Randomized double-blind study of the effectiveness of Gingko biloba extract [Hirnleistungsstorungen vaskularer Genese. Randomisierte Doppelblindstudie zur Wirksamkeit von Gingko-biloba-Extrakt]. Fortschr Med 1988;106(19):408-412
15. Halama P. [Ginkgo biloba.The effectiveness of a special extract for patient with cerebral insufficiency] [Ginkgo biloba. Wirksamkeit eines Spezialextrakts bei Patientenmit zerebraler Insuffizienz]. Munch med Wschr 1991;133:190-194.
16. Halama P. Judgement of well-being and psychometric tests in patients from a neurological practice treated with Ginkgo [Befindlichkeitsbeurteilung und Psychometrie. testung der Ginkgo-biloba-Wirkung bei Patienten einer Neurologischen Fachpraxis]. Munch med Wschr 1991;133(Suppl 1):S19-S22.
17. Hartmann A, Frick M. [The effectiveness of a Ginkgo special extract on psychometric parameters for patients with vascular dementia] [Wirkung eines Ginkgo-Spezial-extraktes auf pychometrische Parameter bei Patienten mit vaskulär bedingter Demenz]. Münch. Med. Wochenschr. 1991;133:S23-S25.
18. * Hofferberth B. The effect of Ginkgo biloba extract on neurophysiological and psychometric measurement results in patients with psychotic organic brain syndrome. A double-blind study against placebo [Einfluss von Ginkgo biloba-Extrakt auf neurophysiologische und psychometrische Messergebnisse bei Patienten mit hirnorganischem Psychosyndrom. Eine Doppelblindstudie gegen Plazebo]. Arzneimittelforschung 1989;39(8):918-922
19. Hofferberth B. Ginkgo-biloba-Spezialextrakt bei Patienten mit hirnorganischem Psychosyndrom. Pruefung der Wirksamkeit mit neurophysiologischen und psychometrischen Methoden [Ginkgo biloba Special Extract treatment in patients with cerebro-organic syndrome. Study on the efficacy with neurophysiological and psychometrical methods]. Munch. Med. Wochenschr. 1991;133:S30-S33.
20. * Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology 1994;9(3):215-222
21. Deberdt W. Interaction between psychological and pharmacological treatment in cognitive impairment. Life Sciences 1994;55(26/26):2057-2066 (Pubitemid 24372595)
22. Israel L, Dell'Accio E, Martin G, Hugonot R. Extrait de ginkgo biloba et exercises d'entrainement de la memoire. Evaluation comparative chez des personnes agees ambulatoires. Pychologie Med. 1987;19:1431-1439 (Pubitemid 18124228)
23. Kade F, Miller W. Dose-dependent effects of Ginkgo biloba extract on cerebral, mental and physical efficiency - a placebo controlled double blind study. British Journal of Clinical Research 1993;4:97-103. (Pubitemid 24092516)
24. Horr R, Kieser M. Ginkgo biloba special extract EGb 761 - an antidementia drug [Ginkgo-biloba-Spezialextrakt EGb 761 - ein Antidementivum]. Fortschritte Der Medizin 1998;116(3):39-40. (Pubitemid 28064603)
25. * Kanowski S, Herrmann WM, Stephan K, Woerich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29(2):47-56.
26. Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36(6):297-303. (Pubitemid 38085148)
27. Haan J, Horr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761. Wien Med Wochenschr 2004;154:511-514 (Pubitemid 40186409)
28. Le Bars PL. Response Patterns of Egb 761 (R) in Alzheimer's Disease: Influence of Neuropsychological Profiles. Pharmacopsychiatry 2003;36(1):S50-S55.
29. * Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group [see comments]. JAMA 1997;278(16):1327-1332
30. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dementia and Geriatric Cognitive Disorders 2000;11(4):230-237 (Pubitemid 30416029)
31. Le Bars PL, Velasco FM, Ferguson JM, Dessain EC, Kieser M, Hoerr R. Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 2002; Vol.45, issue 1:19-26. (Pubitemid 34117724)
32. Por CP, Evans MF. Does ginkgo help delay dementia?. Can Fam Physician 1998;44:997-999
33. Stevermer JJ, Lindbloom EJ. Clinical question: Does an extract of Ginkgo biloba safely alter cognitive and functional outcomes in patients with dementia?. Journal of Family Practice Vol. 46, issue 1:20.
34. Thuro H. [Die Zukunft der Demenztherapie mit Ginkgo-Specialextrakt EGb 761]. Beilage für Nervenzerzte. Munich: Springer, 1997.
35. * Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (Egb) compared to placebo in the treatment of patients affected by senile psychorganic dementia on an arteriosclerotic basic [Effecti clinico-terapeutici dell'estratto di Ginkgo biloba (Egb) in confronto a placebo, affetti da demenza psicorganica senile su base arteriosclerotica]. Gazzetta Medica Italiana - Archivio per le Scienze Mediche 1993;152(3):69-80.
36. * Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of Psychiatric Research 1997;31(6):645-655
37. * Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology 2006;13:981-985.
38. Napryeyenko A, Ihl R, Schlaefke S, Hoerr R. Ginkgo biloba Extract EGb 761® in the Treatment of Dementia with Neuropsychiatric Features: A Randomized, Placebo-controlled, Double-blind Trial. 21st International Conference of Alzheimer's Disease International, Istanbul, Turkey, September 2005. 2005.
39. Napryeyenko O, Borzenko I, for the GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittel Forschung / Drug Research 2007;57:4-11. (Pubitemid 46212982)
40. Scripnikov A, Khomenko A, Napryeyenko O, for the GINDEMNP Study Group. Effects of Ginkgo biloba Extract EGb 761® on neuropsychiatric symptoms of dementia: findings froma randomised controlled trial. Wiener Medizinische Wochenschrift 2007;157(13-14):295-300. (Pubitemid 47356252)
41. * Oswald WD, Horr R, Oswald B, Steger W, Sappa J. Increase of fluid cognitive factors with Ginkgo biloba special extract EGb 761 (R) in elderly patients with mild to moderate organic brain syndrome [Zur Verbesserung fluider, kognitiver Leistungen mit Ginkgo-biloba-Spezialextrakt EGb 761(R) bei Patienten mit leichten bis mittelschweren Hirnleistungsstoerungen im Alter]. Zeitschrift-Fuer-Gerontopsychologie-und-Psychiatrie 1997;10(3):133-146
42. Pidoux B, Bastien C, Niddam S. Clinical and quantitative EEG double-blind study of Ginkgo biloba extract (GBE). J Cerebral Blood Flow and Metabolism 1983;3(Suppl 1):S556-7.
43. * Rai GS, Shovlin C, Wesnes KA. A double-blind, placebo controlled study of Ginkgo biloba extract ('Tanakan') in elderly out-patients with mild to moderate memory impairment. Current Medical Research and Opinion 1991;12(6):350-355.
44. Schmidt U, Rabinovici K, Lande S. Einfluss eines Ginkgo-Spezialextraktes auf die Befindlichkeit bei zerebraler Insuffizienz [Effect of a Ginkgo biloba Special Extract on well-being in cerebral insufficiency]. Munch. Med. Wochenschr. 1991;133(Suppl 1):S15-S18.
45. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimer's Type. Current Alzheimer Research 2005;2:541-551 (Pubitemid 41703672)
46. * Taillandier J, Ammar A, Rabourdin JP, Ribeyre JP, Pichon J, Niddam S, Pierart H. Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter double-blind drug vs. placebo study [Traitement des troubles du vieillissement cerebral par l'extrait de Ginkgo biloba. Etude longitudinale multicentrique a double insu face au placebo]. Presse Med 1986;15(31):1583-1587
47. Barry H. Is ginkgo biloba effective in managing memory problems in the elderly?... commentary on van Dongen MCJ, van Rossum E, Kessels AGHet al. The efficacy if [sic] ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized controlled trial. J AM GERIATR SOC 2000;48:1183-94.
48. Evidence Based Practice 2001; Vol.4, issue 2:4.
49. van Dongen MCJM. Efficacy of Ginkgo biloba in dementia and cognitive decline. PhD thesis. Department of Epidemiology, Maastricht University, 1999.
50. van Dongen MCJM, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associatedmemory impairment: new results of a randomized clinical trial. J American Geriatrics Society 2000;48:1183-1194
51. Vesper J, Hansgen K-D. Efficacy of Ginkgo biloba in 90 outpatients with cerebral insufficiency caused by old age. Results of a placebo-controlled double-blind trial. Phytomedicine 1994;1:9-16.
52. Vorberg G, Schenk N, Schmidt U. Wirksamkeit eines neuen Ginkgo-biloba-Extraktes bei 100 Patienten mit zerebraler Insuffizienz. Herz + Gefässe 1989;9(7):396-401.
53. * Weitbrecht von W-U, Jansen W. Primary degenerative dementia: therapy with Ginkgo biloba extract. Placebo-controlled double-blind and comparative study [Primar degenerative Demenz: Therapie mit Ginkgo-biloba- Extrakt. Plazebo-kontrollierte Doppelblind- und Vergleichsstudie.]. Fortschr Med 1986;104(9):199-202.
54. Weitbrecht WV, Jansen W. Doubleblind and comparative (Ginkgo biloba versus placebo) therapeutic study in geriatric patients with primary degenerative dementia - a preliminary evaluation. In: Agnoli A, Rapin JR, Scapagnini V, Weitbrecht WV editor(s). Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment. Montrouge: John Libby Eurotext Ltd, 1985:91-99.
55. * Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly.. Human-Psychopharmacology-Clinical-and-Experimental 1987;2(3):159-169
56. * Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, d'Arbigny P. Effect of two doses of Ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects.. Clinical-Therapeutics:-The-International-Journal-of-Drug- Therapy 1993;15(3):549-558
57. Ercoli EM, Small GW, Silverman DGS, Siddarth P, Dorsey D, Miller K, Kaplan A, Skura S, Byrd G, Huang SC, Phelps ME. The effect of Ginkgo Biloba on cognitive and cerebral metabolic function in age-associated memory impairment. Annual Meeting of the Society for Neuroscience, New Orleans. LA. Nov. 8-12. 2003. 2003.
58. * Erdincler DS, Karakoc Y, Toplan S, Onen S, Sukyasyan A, Beger T, Demiroglu C. The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clinical Hemorheology 1996;16(3):271-276
59. Franco L CGNF. Etude multicentrique de l'efficacite de l'extrait de Ginkgo Biloba (EGB 761) dans le traitement des troubles mnesiques lies a l'age.. La Revue De Geriatrie 1991;16:191-195
60. * Gerhardt von G, Rogalla K, Jaeger J. Drug therapy of disorders of cerebral performance. Randomized comparative study of dihydroergotoxine and Ginkgo biloba extract [Medikamentose Therapie von Hirnleistungsstorungen. Randomisierte Vergleichsstudie mit Dihydroergotoxin und Ginkgo-biloba-Extrakt.]. Fortschr Med 1990;108(19):384-388
61. Gessner B VAKM. Study of the long term action of a Ginkgo Biloba extract on vigilance andmental performance as determined bymeans of quantitative pharmaco-EEG and psychometric measurements.. Arzneim. Forsch./Drug Res. 1985;35:1459-1465
62. Gomez GA. Multicenter study with standardized extract of Ginkgo -Biloba EGB 761 in the treatment of memory alteration, vertigo and tinnitus [Estudio multicentrico del extracto estandardizado de Ginkgo biloba en el tratamiento de los trastornos de la memoria, vertigo y tinnitus]. Invest Med Int 1997;24(2):31-39
63. Haan J RUWFSGME. Ginkgo-Biloba-Flavonglykoside. Therapiemoeglichkeit der zerebraler Insufficienz.. Med. Welt 1982;33:1001-1005
64. Heinen Kammerer T, Motzkat K, Daniel D, Gertz HJ, Koller M, Lorenz W, Pilartz H, Zimmer B, Habs M, Von Den Driesch V, Rychlik R. The situation of patients with dementia may be rectified by ginkgo biloba. MMW Fortschritte der Medizin 2005;147(42):51. (Pubitemid 41596296)
65. Israël L, Ohlman T, Delomier Y, Hugonot R. Étude psychométrique de l'activité d'un extrait végétal au cours des états d'involution sénile.. Lyon Mediterranee Medical 1977;13(16):1197-1199
66. Itil T, Martorano D.Natural substances in psychiatry (Ginkgo biloba in dementia).. Psychopharmacol Bull 1995;31(1):147-158
67. * Itil TM, Erapl E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull 1998;34(3):391-397
68. * Koltringer P, Langsteger W, Eber O. Dose-dependent hemorheological effects and microcirculatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761. CLIN-HEMORHEOL 1995;15(4):649-656.
69. Moreau P. Un nouveau stimulant circulatoire cerebral.. La Nouvelle Presse Medicale 1975;4:2401-2402
70. * Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers.. Phytother Res 1999;13(5):408-415
71. Schultz SK. Cognitive enhancers explored with PET imaging. Clinical Trials.gov 2002:1-3.
72. * Schulz H, Jobert M, Breuel H-P. Wirkung von Spezialextrakt LI1370 auf das EEG älterer Patienten im Schlafentzugsmodell [Wirkung von Spezialextrakt LI1370 auf das EEG älterer Patienten im Schlafentzugsmodell] . Münch. Med. Wochenschr. 1991;133(Suppl 1):S26-S29.
73. * Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA. Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment.. Pharmacopsychiatry 1995;28(4):134-142
74. Teigeler R PL. Ginkgo Biloba bei zerebraler Insuffizienz.. Artzliche Praxis 1984;36:1374.
75. * Vorberg G. Ginkgo Biloba Extract (GBE) - A long-term Study of chronic cerebral insufficiency in geriatric patients. Clinical Trials Journal 1985;22:149-157
76. * Wesnes KA, Faleni RA, Hefting NR, Hoogsteen G, Houben JJG, Jenkins E, Jonkman JHG, Leonard J, Petrini O, Lier JJ van. The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints.. Psychopharmacol Bull 1997;33(4):677-683
77. Winther K, Randlov C, Rein E, Mehlsen J. Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. Current Therapeutic Research 1998;59(12):881-888 (Pubitemid 29014312)
78. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The Guid Age study: Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761(R) for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006;67(9 Suppl 3):S6-S11. (Pubitemid 44684670)
79. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition. DSM-IV. Washington, DC: American Psychiatric Association, 1994.
80. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. In: Pichot P editor(s). Psychological Measurements in Psychopharmacology. Mod Probl Pharmacopsychiatry 7. Basel: Karcher, 1974:151-169
81. Bedard M, Molloy D, Squire L, et al.The Zarit Burden Interview: a new short version and screening version. Gerontologist 2001;41(5):652-657 (Pubitemid 32959731)
82. Benton AL. Revised visual retention test. 4th Edition. New York: Psychological Corporation, 1974.
83. Bråne G, Gottfreis CG, Winblad B. The GBS scale: validity, reliability and application in anti-dementia drug trials.. Dementia, Geriatric and Cognitive Disorders 2001;12:1-14. (Pubitemid 32010737)
84. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression scale: A comparison with the 30-item form. Journal of Geriatric Psychiatry and Neurology 1991;4:173-178
85. Chang JY, Chang MN. Medicinal uses of Ginkgo biloba. TODAY'S-THER-TRENDS: Today's-Therapeutic-Trends 1997;15(1):63-74.
86. Cohen RJ, Montaque P, Nathson LS, Swerdlik ME. Psychological Testing. An introduction to Tests & Measurement. Mountain View, CA: Mayfield Publishing Company, 1988.
87. Cummings J, Mega M, Gray K, et al.The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-2314. (Pubitemid 24382728)
88. Curtis-Prior P, Vere D, Fray P. Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. Journal of Pharmacy and Pharmacology 1999;51(5):535-541 (Pubitemid 29319778)
89. De Feudis F. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Weisbaden, Germany: Ullstein Med, 1998.
90. DeJong R, Osterlund OW, Roy GW.Measurement of quality-of-life changes in patients with Alzheimer's disease. Clinical Therapeutics 1989;11(4):545-554. (Pubitemid 19202105)
91. Ernst E, Pittler MH. Ginkgo biliba for dementia A systematic review of double-blind, placebo controlled trials. Clin Drug Invest 1999;17(4):301-308 (Pubitemid 29204549)
92. The EuroQol Group. EurolQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208.
93. Folstein MF, Folstein DE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975;12:189-198.
94. Gottfries CG, Bråne G, Gullberg B, Steen G. A new rating scale for dementia syndromes. Archives of Gerontology and Geriatrics 1982;1:311-330 (Pubitemid 13153548)
95. Guy W. Clinical Global Impression of Change. In: Guy W editor (s). 'ECDEU Assessment manual for Psychopharmacology, revised. US Department of Health, Education, and Welfare, Rockville, 1976.
96. Hamilton M. A rarting scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
97. Hopfenmüller W. Evidence for a therapeutic effect of Ginkgo biloba special extract. Meta-analysis of 11 clinical studies in patients with cerebrovascular insufficiency in old age [Nachweis der therapeutischen Wirksamkeit eines Ginkgo biloba-Spezialextraktes. Meta-Analyse von 11 klinischen Studien bei Patienten mit Hirnleistungsstörungen im Alter]. Arzneimittelforschung 1994;44(9):1005-1013
98. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34(4):352-358
99. Knipschild P, van Dongen M, van Rossum E, Kleijnen J. Clinical experience with ginkgo in patients with cerebral insufficiency. Rev Bras Neurol 1994;30(Suppl 1):18S-25S. (Pubitemid 24288179)
100. Lindeboom J, Koene T, Matto D. [De diagnostische waardevan tests voor mentale controle]. Tijdschrift voor Gerontologieen Geriatrie 1993;24:105-109
101. Logsdon R, Gibbons L, McCurry S, et al.Quality of life in Alzheimer's disease: patient and caregiver reports.. Journal of Mental Health and Ageing 1999;5:21-32. (Pubitemid 29235115)
102. Massey AJ. Effectiveness of ginkgo biloba in memory disorders. J-PHARM-PRACT: Journal-of-Pharmacy-Practice1999;12(3):217-224
103. McKhann G, Drachman D Folstein M, et al.Clinical diagnosis of Alzheimer's disease: report fo the NINDCS-ARDRA Work Group under the auspices of the Department of Health and Human Sciences Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 (Pubitemid 14076461)
104. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.. Arch Neurol 1998;55(11):1409-1415 (Pubitemid 28525500)
105. Oswald WD, Fleischmann UM. Nürnberger-Alters-Inventar (NAI: Nuremberg Gerontopsychological Inverntory). Nürnberg: Universität ERlangen-Nürnberg, Psychologisches Institut II, 1986.
106. Oswald WD, Fleischmann UM. Nürnberger Alters Inventar (NAI). NAI-Testmanual und Textband. 3rd Edition. Gottingen: Hogrefe, 1995.
107. Overall JE, Schalten R. The SKT neuropsychological test battery. Journal of Geriatric Psychiatry and Neurology 1992;5:220-227.
108. Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982;139:1136-1139 (Pubitemid 12051593)
109. Robinson RA. The diagnosis and prognosis of dementia. In: Anderson WE editor(s). Current Achievements in Geriatrics. London: Cassell, 1964:190-203.
110. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Annals of Neurology 1980;7:486-488.
111. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimers' disease. American Journal of Psychiatry 1984;141(11):1356-64..
112. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestin of Ginkgo biloba extract. New England Journal of Medicine 1997;336:1108. (Pubitemid 27163872)
113. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-1777
114. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al.Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S22-S32. (Pubitemid 27303107)
115. Schwartz GE. Development and validation of the Geriatric Evaluation of Relative's Rating Instrument (GERRI). Psychol Rep 1983;53:479-488
116. Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). J Am Ger Soc 1974;22:107-113.
117. Søholm B. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: Review of relevant literature. Advances in Therapy 1998;15(1):54-65. (Pubitemid 28125337)
118. Van Dongen MCJM, van Rossum E, Knipschild P. Efficacy of Ginkgo biloba special extracts - Evidence from randomized clinical trials. In: van Beek TA editor(s). Ginkgo biloba. Amsterdam: Harwood Academic, 2000.
119. Warburton 1986. Clinical psychopharmacology of Ginkgo biloba extract [Psycho-pharmacologie clinique de l'extrait de Ginkgo biloba]. La Presse Médicale 1986;15(3):1595-1604.
120. Wechsler D. A standardized memory scale for clinical use. Journal of Psychology 1945;19:87-95.
121. Yesavage JA, Brink TL, Rose TL, et al.Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric Research 1982;17:37-49.
122. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD003120.pub2] (Pubitemid 351805772)